Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

Keating GM.

Drugs. 2013 May;73(6):575-93. doi: 10.1007/s40265-013-0051-1. Review.

PMID:
23620200
[PubMed - indexed for MEDLINE]
2.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
[PubMed - indexed for MEDLINE]
3.

Insulin detemir: a review of its use in the management of diabetes mellitus.

Keating GM.

Drugs. 2012 Dec 3;72(17):2255-87. doi: 10.2165/11470200-000000000-00000. Review.

PMID:
23110609
[PubMed - indexed for MEDLINE]
4.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
[PubMed - indexed for MEDLINE]
5.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators.

Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.

PMID:
23710902
[PubMed - indexed for MEDLINE]
Free Article
6.

Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin.

Josse RG, Woo V.

Diabetes Obes Metab. 2013 Dec;15(12):1077-84. doi: 10.1111/dom.12114. Epub 2013 May 6. Review.

PMID:
23577589
[PubMed - indexed for MEDLINE]
7.

Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.

Chapman TM, Noble S, Goa KL.

Drugs. 2002;62(13):1945-81. Review. Erratum in: Drugs. 2003;63(5):512..

PMID:
12215068
[PubMed - indexed for MEDLINE]
8.

Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.

Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI.

Diabet Med. 2012 Jun;29(6):716-20. doi: 10.1111/j.1464-5491.2011.03547.x.

PMID:
22150786
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan V, Gouet D, Marre M, Renard É.

Ann Endocrinol (Paris). 2013 Dec;74(5-6):487-90. doi: 10.1016/j.ando.2013.04.004. Epub 2013 Aug 23.

PMID:
23978337
[PubMed - indexed for MEDLINE]
10.

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.

Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.

Eur J Endocrinol. 2012 Aug;167(2):287-94. doi: 10.1530/EJE-12-0293. Epub 2012 Jun 1. Erratum in: Eur J Endocrinol. 2012 Sep;167(3):453.

PMID:
22660026
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R.

Diabet Med. 2013 Feb;30(2):226-32. doi: 10.1111/dme.12086.

PMID:
23199058
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, King A, Mersebach H, Davies M.

Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.

PMID:
22933438
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Insulin degludec: overview of a novel ultra long-acting basal insulin.

Gough SC, Harris S, Woo V, Davies M.

Diabetes Obes Metab. 2013 Apr;15(4):301-9. doi: 10.1111/dom.12052. Epub 2013 Jan 29. Review.

PMID:
23240573
[PubMed - indexed for MEDLINE]
14.

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.

Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C; BEGIN Once Long trial investigators.

Diabet Med. 2013 Nov;30(11):1298-304. doi: 10.1111/dme.12303. Epub 2013 Sep 30.

PMID:
23952326
[PubMed - indexed for MEDLINE]
15.

Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile.

Rendell M.

Drugs Today (Barc). 2013 Jun;49(6):387-97. doi: 10.1358/dot.2013.49.6.1976051. Review.

PMID:
23807942
[PubMed - indexed for MEDLINE]
16.

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.

Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S.

Diabetes Obes Metab. 2013 Sep;15(9):826-32. doi: 10.1111/dom.12097. Epub 2013 Apr 5.

PMID:
23557077
[PubMed - indexed for MEDLINE]
17.

Insulin during pregnancy, labour and delivery.

de Valk HW, Visser GH.

Best Pract Res Clin Obstet Gynaecol. 2011 Feb;25(1):65-76. doi: 10.1016/j.bpobgyn.2010.10.002. Epub 2010 Dec 24. Review.

PMID:
21186142
[PubMed - indexed for MEDLINE]
18.

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C.

Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7.

PMID:
21396703
[PubMed - indexed for MEDLINE]
19.

A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.

Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T.

J Diabetes Sci Technol. 2013 Sep 1;7(5):1328-36.

PMID:
24124961
[PubMed - indexed for MEDLINE]
20.

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B.

Diabetes Obes Metab. 2013 Feb;15(2):175-84. doi: 10.1111/dom.12032. Epub 2012 Dec 3.

PMID:
23130654
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk